BioLineRx BLRX
NASDAQ BLRX
$2.32 -0.02 (-0.85%)
At close: Oct 2, 2026 · 4:00 PM EDT

BioLineRx (BLRX) Return on Equity [ROE] (2013 - 2026)

Updated

BioLineRx's Return on Equity [ROE] was -59.88% in the quarter ended Jun 30, 2026, down 18.09 percentage points from -41.79% a year earlier and down 10.92 percentage points from the prior quarter.

Analysis

BioLineRx (BLRX) Return on Equity [ROE] (2013 - 2026) Analysis & Trends

For the year ended Dec 31, 2025, Return on Equity [ROE] at BioLineRx came in at -11.01%, up 58.10 percentage points from the prior year.

  • Return on Equity [ROE] shows a five-year change of +97.35 percentage points (years ended Dec 2020 to Dec 2025).
  • In earlier years, Return on Equity [ROE] was -69.11% in the year ended Dec 31, 2024 (+120.12 pp), -189.23% in the year ended Dec 31, 2023 (-147.27 pp), -41.96% in the year ended Dec 31, 2022 (+18.08 pp) and -60.04% in the year ended Dec 31, 2021 (+48.32 pp).
  • The figure for the quarter ended Jun 30, 2026 marks the lowest quarterly Return on Equity [ROE] since the quarter ended Sep 30, 2024.
  • Compared with a year earlier, Return on Equity [ROE] has declined for three straight quarters, with an average year-over-year change of +143.98 percentage points over the last eight quarters.
  • The best year-over-year quarter for Return on Equity [ROE] over five years was the quarter ended Dec 31, 2024 (a gain of 431.43 percentage points); the worst was the quarter ended Dec 31, 2023 (a drop of 411.76 percentage points).
  • Per Business Quant data, BLRX's Return on Equity [ROE] in the three quarters before the quarter ended Jun 30, 2026 was -48.96% (quarter ended Mar 31, 2026), -46.39% (quarter ended Dec 31, 2025) and -34.10% (quarter ended Sep 30, 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 25.32%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 7.21%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 84.40%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 21.39%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 83.75%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -18.38%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.97%
10 BioLineRx 6.06 Bn 6.06 Bn 235,000.00 -59.88%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -59.88%
Mar 31, 2026 -48.96%
Dec 31, 2025 -46.39%
Sep 30, 2025 -34.10%
Jun 30, 2025 -41.79%
Mar 31, 2025 -24.07%
Dec 31, 2024 -28.67%
Sep 30, 2024 -197.98%
Jun 30, 2024 -222.91%
Mar 31, 2024 -374.14%
Dec 31, 2023 -460.10%
Sep 30, 2023 -284.01%
Jun 30, 2023 -146.40%
Mar 31, 2023 -73.24%
Dec 31, 2022 -48.34%
Sep 30, 2022 -41.71%
Jun 30, 2022 -37.33%
Mar 31, 2022 -33.14%
Dec 31, 2021 -38.93%
Sep 30, 2021 -47.98%
API Access

BioLineRx Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=BLRX&period=max&api_key=YOUR_API_KEY